3 days ago · “As Lantheus continues to advance its industry leadership, this transaction, along with the agreement to acquire Life Molecular Imaging, enhances our operations across the radiopharmaceutical value chain,” said Brian Markison, CEO of Lantheus. “With Evergreen’s manufacturing and development capabilities, we become fully integrated and ...

3 days ago · Lantheus Logo. This transaction is expected to solidify Lantheus' capabilities as a fully integrated radiopharmaceutical company. The addition of Evergreen's scalable manufacturing capabilities ...

1 day ago · The US radiopharmaceuticals giant Lantheus is snapping up the Contract Development and Manufacturing (CDMO) Evergreen Theragnostics as it expands its radiopharmaceuticals business. The deal, which is expected to close in late 2025, is intended to absorb Evergreen’s manufacturing capabilities and radiopharmaceutical pipeline.

1 day ago · US-based radiopharmaceutical company Lantheus has announced a definitive agreement to acquire clinical-stage radiopharma contract development and manufacturing organisation (CDMO) Evergreen Theragnostics. Lantheus will make an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.

2 days ago · “As Lantheus continues to advance its industry leadership, this transaction, along with the agreement to acquire Life Molecular Imaging, enhances our operations across the radiopharmaceutical value chain,” said Brian Markison, CEO of Lantheus. “With Evergreen’s manufacturing and development capabilities, we become fully integrated and ...

3 days ago · Evergreen’s ability to work with a variety of diagnostic and therapeutic isotopes will enhance Lantheus’ ability to address the complexities of radiopharmaceutical development and production.

2 days ago · Lantheus will add Evergreen’s radiogland therapy manufacturing infrastructure, including its “revenue generating” contract development and manufacturing organization. Adding in-house radiopharma development expertise allows Lantheus to supply its clinical trials, scale manufacturing and commercial launches and “mitigate third-party risk

3 days ago · Lantheus will acquire Evergreen Theragnostics for $250 million upfront, plus up to $752.5 million in milestone payments, closing in H2 2025. The Life Molecular Imaging acquisition adds Neuraceq to ...

2 days ago · New York – January 28, 2025 – Cooley advised Lantheus Holdings (Nasdaq: LNTH), a radiopharmaceutical-focused company committed to enabling clinicians to find, fight and follow disease to deliver better patient outcomes, on its definitive agreement to acquire Evergreen Theragnostics.Under the terms of the agreement, Lantheus will pay an upfront amount of $250 million in cash at closing and ...

2 days ago · Lantheus Holdings Inc., a radiopharmaceutical healthcare company, announced Tuesday its plans to acquire Evergreen Theragnostics Inc. for up to $1 billion, marking a significant expansion of its capabilities in radiopharmaceutical development and manufacturing. The deal involves an upfront cash payment of $250 million and up to $752.5 million in milestone payments, according to a company ...